• Fbxl10 is a bona fide oncogene in vivo.
Introduction
Appropriate patterns of epigenetic alterations in histone modifications are required to assure cell identity, and their deregulation can contribute to human diseases such as cancer 1 . We previously generated knockout (KO) mice for Samd9L, which was cloned as a candidate gene for the −7/7q− syndrome frequently that is observed in myelodysplastic syndrome and acute leukemia patients, and demonstrated that mice deficient in Samd9L developed leukemia after a long latent period 2 . In addition, retroviral insertional mutagenesis revealed that the onset of the disease was highly accelerated with upregulation of F-box and leucine-rich repeat protein 10 (Fbxl10) or ectopic virus integration 1 (Evi1) 2 . Clinically, an elevated expression of Fbxl10 is observed in patients with acute myeloid or lymphoid leukemia, seminoma and pancreatic ductal adenocarcinoma [3] [4] [5] [6] . These findings prompted us to further investigate the role of Fbxl10 in leukemia development in vivo.
Fbxl10 belongs to the JmjC domain-containing histone demethylases, and
contains an N-terminal JmjC domain, followed by a CXXC zinc finger domain, a PHD finger, an F-box, and eight leucine-rich repeats 7 . Fbxl10 preferentially demethylates the dimethylation of histone H3 at lysine 36 (H3K36me2), but not H3K36me1 and H3K36me3 6, 8 . Fbxl10 was also recently reported to mediate the monoubiquitination of the histone H2A at lysine 119 as a component of non-canonical polycomb repressive complex 1 in embryonic stem (ES) cells 9, 10 . Several lines of evidence have so far suggested that Fbxl10 is a tumor accelerator. Overexpression of Fbxl10 in fibroblasts inhibited cellular senescence by repressing p16ink4a-p19Arf and p15ink4b loci in mouse as well as Rb and p53 loci in humans, resulting in cellular immortalization 6, 11 . In addition, wild-type (WT) Fbxl10 but not a demethylase activity-deficient mutant, accelerated the progression of pancreatic cancer in a mouse allograft model Furthermore, another study demonstrated that the demethylase enzymatic activity was required for leukemic transformation in a Hoxa9-Meis1-induced mouse BM transplantation model 13 . These findings suggest that Fbxl10 contributes to the development of tumor in vivo.
Genomic and functional studies have identified two broad classes of mutations that cooperate during the development of acute leukemia 14, 15 . Class I mutations confer a proliferative and/or survival advantage of HSCs and progenitor cells.
Class II mutations are associated with impaired hematopoietic differentiation 14, 15 . As a simplified model, it has been proposed that growth advantage together with impaired differentiation is required for the development of the acute leukemia phenotype. In this study, we report that Fbxl10 Tg mice that overexpress Fbxl10 in HSCs spontaneously develop leukemia involving these Class I/Class II mutation-mimetic properties.
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Methods

Generation of Fbxl10 transgenic mice
Murine Fbxl10 cDNA with an Flag tag at the 3′ end was inserted at the ClaI site of the Ly-6A transgenic cassette (pLy-6A14) that encompasses the mouse Sca-1 gene 1 6 , 1 7 . A fragment containing the Sca-1 promoter, Fbxl10 cDNA with Flag tag and Sca-1 3′ locus control regions was excised and microinjected into the pronuclei of C57BL/6N mice.
All the mice were kept according to the guidelines of the Institute of Laboratory Animal Science, Hiroshima University.
Statistics
Mouse survival curves were constructed using the Kaplan-Meier methodology and compared by the log-rank test using the GraphPad Prism software. Other statistical analyses were performed using the Student's t-test, unless otherwise stated.
A complete and detailed description of methods can be found in Supplemental Methods.
Results
Fbxl10 transgenic mice spontaneously develop myeloid and B-lymphocytic leukemias
The Sca-1 gene promoter is activated in functional repopulating adult HSCs in mice and has been so far widely available for Tg research [16] [17] [18] [19] . To achieve Tg expression of Fbxl10 in mice, the Flag-tagged mouse Fbxl10 cDNA was inserted into the cloning site of the Ly6A/Sca-1 Tg cassette that allows high expression in the HSC compartment 17 (Supplemental Figure 1A) . We confirmed a more than 10-fold upregulation of Fbxl10 mRNA in Sca-1 + cells in two independent lines (lines #3 and #4) (Supplemental Figure 1B) , both of which provided similar results in this study (thus, hereafter we refer mice in both lines as to Fbxl10 Tg mice). We found that the expression levels of Fbxl10 mRNA were higher in Tg cells than control cells in all the compartments, especially in HSC-early progenitor fractions (Supplemental Figure 1C) . This is consistent with the result of the initial study reporting that the same Sca-1 promoter used in this study is vigorously active predominantly in murine HSCs
17
. The overexpression of the Fbxl10 protein was confirmed by immunoprecipitation followed by Western blot using an anti-Flag antibody (Supplemental Figure 1D) Figure 1E) . One possible explanation for decreased H3K36me2 levels in Sca-1 − cells may be that Fbxl10 protein was sustained in Sca-1 − progenitor and other differentiated populations.
We followed 30 Tg and 20 control littermates over a 1.5-year period.
Interestingly, all the Fbxl10 Tg mice developed acute leukemias and died during the observation period (median survival = 367 days), whereas no hematopoietic disease was observed in the wild-type mice ( Figure 1A ). All moribund Tg mice showed Leukemic cells from 14 of the 25 tested mice were abundantly positive for both Gr1 and Mac1 and were accordingly diagnosed as acute myeloid leukemia (AML) (Tg-1 in Figure 1C and Supplemental Table 1 ). Seven mice were diagnosed as acute B-lymphocytic leukemias (B-ALL), in which B220 + cells dominantly proliferated (Tg-2 in Figure 1C and Supplemental Figure 2) .
To further assess the tumor susceptibility caused by the expression of Fbxl10, neonate mice were infected with replication competent MOL4070LTR mouse leukemia retrovirus, which is capable of inducing both myeloid disease and lymphoid diseases 20 .
The injection of MOL4070LTR profoundly accelerated the onset of the disease in the Figure 4C) . These results suggest that Fbxl10 enhances self-renewal activity and a long-term BM repopulation capacity with a lasting myeloid and B-lymphoid expansion in the peripheral blood in a cell-autonomous manner.
Nsg2, a neuron-specific gene aberrantly induced by Fbxl10, impairs hematopoietic differentiation in vitro
To elucidate the mechanistic link between the overexpression of Fbxl10 and development of leukemia, we analyzed the transcriptional profiles of IL-7Rα − LSK hematopoietic stem cells in non-leukemic young Tg mice (eight weeks of age) together with the corresponding controls ( Table 1) . A remarkable observation was the markedly increased expression of Nsg2 (also known as HMP19), encoding a 19kDa protein localized in the golgi apparatus 21 , in Tg cells ( Figure 3A and Table 1 ). We found that the levels of Nsg2 mRNA were low in control HSCs (Table 1) , whereas a 40-fold higher expression was observed in the Tg HSCs ( Figure 3B ). A significantly higher expression of Nsg2 was also detected in most of the Fbxl10 Tg leukemic tissues of myeloid lineage ( Figure 3C ), suggesting that Nsg2 may be implicated in the pathogenesis of leukemia.
To assess this possibility, we performed siRNA knockdown in cells prepared from a Tg leukemic spleen diagnosed as AML exhibiting high Nsg2 expression (mouse No.8 in Figure 3C and Supplemental Table 1 
Fbxl10-overexpressing HSCs are metabolically active and characterized by an increased oxidative phosphorylation
Previous studies have reported that Fbxl10 suppresses senescence-associated cyclin-dependent kinase inhibitors (CDKIs) such as p15ink4b, p16ink4a, p18ink4c, and p57kip2 in murine blood cells 12, 13 . Therefore, we investigated the possibility that suppression of these CDKI genes might account for the survival/proliferation advantage in Tg HSCs, which is reminiscent of the canonical Class I mutations. The former two genes, p15ink4b and p16ink4a were very weakly expressed in primary control HSCs, as reported in a previous transcriptome analysis 22 ; no expressional change of these genes was observed in Tg HSCs. The latter two genes, p18ink4c and p57kip2, were expressed in both genotypes and slightly suppressed by 20%-45% in Tg HSCs as compared with wild-type cells (Supplemental Table 2 ). Although the suppression of p57kip2 was most remarkable, this would not account for the enhanced self-renewal activity of Fbxl10 Tg HSCs, because a previous report showed that p57kip2 was required for HSC quiescence and its deficiency abrogated the self-renewal capacity of HSCs in mice 23 .
To identify the differentially regulated functional networks accounting for growth advantage of HSCs in Tg mice, we applied gene set enrichment analysis (GSEA) to the KEGG pathway, a database that represents molecular interaction networks, including metabolic pathways, regulatory pathways, and molecular complexes. This analysis revealed that in non-leukemic Tg HSCs, several gene sets were significantly upregulated with "Oxidative phosphorylation (OXPHOS)" being the highest ( Figure 4A and Table 2 ), whereas no gene sets were significantly downregulated, as compared with the control HSCs. The genes involved in OXPHOS were also most markedly enriched in the leukemic tissues compared with the corresponding controls (Figure 4B-C and Table 3 ). Adenosine 5′-triphosphate (ATP) is the central cellular metabolic marker and bioenergetic source 24, 25 . We observed a significant increase in basal intracellular ATP content in IL-7Rα − LSK HSCs purified from non-leukemic Fbxl10 Tg mice compared with the corresponding controls ( Figure   4D ). These results strongly suggest that Fbxl10 metabolically activates HSCs by increasing OXPHOS, which is linked to the progression of cell cycle and promotes the development of leukemia.
Fbxl10 has direct and indirect effects in pro-leukemogenic gene expression profiles
To investigate the regulatory mechanism of the pro-leukemogenic transcription signature caused by the overexpression of Fbxl10, we performed chromatin immunoprecipitation sequencing (ChIP-seq) in Tg and control HSCs (LSKs) using a ChIP-grade polyclonal antibody for Since Fbxl10 is an H3K36me2 demethylase, we also performed the ChIP-seq for HSCs using an anti-histone H3K36me2 antibody shown to be applicable for the ChIP-seq 27 .
The result revealed that Fbxl10 overexpression in HSCs reduced H3K36me2 levels more around TSSs (Supplemental Figure 6A-B) . The H3K36me2 ChIP-seq reads were, however, detected at low levels on Fbxl10-targeted regions of Figure 5A and 5C in control HSCs, and therefore, it was unable to clarify the corresponding decrease in reads in Tg HSCs. Figure 7B ). In addition, the primer set was able to detect reduced DNA binding for H3K36me2 in this tumor line (Supplemental Figure 7C) . These results suggest that the ectopic expression of Nsg2 in Tg HSCs is targeted by the overexpression of Fbxl10 and A subpopulation of AML patients exhibits high expression of both HMP19 and
FBXL10
To investigate the potential relevance of the findings to human disease, we investigated the expression levels of HMP19 (human homologue of Nsg2) and FBXL10 on the Cancer Genome Atlas (TCGA) database 28 . We found that HMP19 mRNA was strongly (Figure 6A-B) . These data may support that our mouse model is clinically-relevant with a specific population of leukemia patients.
For 29 . In this study, we used a genetically engineered mouse system to show that the Tg expression of an epigenetic regulator Fbxl10 induced acute leukemias ( Figure   1 ).
Mechanistically, Fbxl10 confers HSCs on the progression of cell cycle through the metabolic activation, whereas Fbxl10 activated the expression of Nsg2, which predisposes hematopoietic stem/early progenitor cells to an undifferentiated state.
Thus, elevated levels of Fbxl10 involve both Class I-and Class II-like properties (Figure 7) . However, the mice did not show an evident HSCs differentiation block at a steady state, and the development of leukemia in Tg mice required a long latency.
Although these properties may underlie tumor susceptibility, additional genetic event(s)
and/or microenvironmental effects may be required for full transformation (Figure 7 ).
This idea was validated by the results that leukemogenesis in Tg mice is drastically accelerated by retrovirus insertional mutagenesis or a carcinogenic mutagen (Figure
1D-E).
Although the biological function of Nsg2 has not been fully understood so far, structurally similar transmembrane molecules NEEP21 (also known as Nsg1) and Caly (also known as Nsg3) are crucial for glutamine and/or dopamine receptor sorting through endosomes and their recruitment to the plasma membrane in neural cells [30] [31] [32] . 38 . In addition, GSEA revealed that genes involved in ribosomal biogenesis were also enriched in both Tg HSCs and leukemic tissues (Tables 2 and 3) , which would provide a direct connection between metabolic activation and the development of tumor because increased protein synthesis is a highly energy demanding process.
Fbxl10 was recently reported to promote K-RAS-mutated pancreatic cancer
through upregulating a module of metabolic genes involved in OXPHOS in a mouse allograft model 5 . In addition, IMP2-positive glioma and PPARGC1A (PGC1α)-positive melanoma showed tumor progression associated with mitochondrial energy activation in the absence and presence of enhanced ROS levels, respectively 39, 40 . Thus, despite the general enhancement of glycolytic bioenergetic requirements in many cancers (so called as "Warburg effect"), several recent studies have revealed unanticipated tumor metabolism by Warburg, i.e., the bioenergetic type of tumors can vary widely from glycolysis to OXPHOS [41] [42] [43] [44] . Our findings suggest that OXPHOS-mediated metabolic activation provides a bioenergetic source to promote leukemogenesis in Fbxl10-upregulated HSCs. However, a number of questions remain to be answered, including the lineage specificity of leukemia and the possible involvement of other factors in Fbxl10 induced-leukemogenesis. The search for these effectors will no doubt contribute to elucidating the mechanism by which overexpressed Fbxl10 leads to leukemia.
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